Search

Your search keyword '"Andreotti F."' showing total 47 results

Search Constraints

Start Over You searched for: Author "Andreotti F." Remove constraint Author: "Andreotti F." Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
47 results on '"Andreotti F."'

Search Results

3. Optimized modelling of maternal ECG beats using the stationary wavelet transform

4. Ion channel inhibition with amiodarone or verapamil in symptomatic hospitalized nonintensive-care COVID-19 patients: The ReCOVery-SIRIO randomized trial

6. Bleeding Complications in Patients Undergoing Percutaneous Coronary Intervention

7. New EHJ Team on Thrombosis

8. Clinical epidemiology and costs of type 2 diabetic patients with or without prior coronary artery disease or stroke. A longitudinal 5-year claims-data analysis of over 7 million inhabitants

10. Antithrombotic Therapy in High Bleeding Risk, Part I: Percutaneous Cardiac Interventions.

11. Acute Coronary Syndrome in Elderly Patients: How to Tackle Them?

12. 2024 ESC Guidelines for the management of chronic coronary syndromes.

15. Letter by Andreotti et al Regarding Article, "Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13 970 Contemporary High-Risk Patients With Statin Intolerance".

17. How to Manage Beta-Blockade in Older Heart Failure Patients: A Scoping Review.

18. Thrombosis, Bleeding, and the Promise of Factor XI(a) Inhibition.

20. Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension.

21. Current concepts in coronary artery revascularisation.

22. Impact of coronary stenting on top of medical therapy and of inclusion of periprocedural infarctions on hard composite endpoints in patients with chronic coronary syndromes: a meta-analysis of randomized controlled trials.

23. [Managing patients with left ventricular thrombosis after acute myocardial infarction: current evidence, uncertainties, and future perspectives].

24. Parenteral Antiplatelet Drugs in ST-Elevation Myocardial Infarction: Current Status and Future Directions.

25. Oral anticoagulants in fragile patients with percutaneous endoscopic gastrostomy and atrial fibrillation: the ORIGAMI pilot investigation.

26. Platelet P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention: An Emerging Option for Antiplatelet Therapy De-escalation.

27. PCSK9 Inhibition During the Inflammatory Stage of SARS-CoV-2 Infection.

28. Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on Thrombosis

30. Myocardial Cell Preservation from Potential Cardiotoxic Drugs: The Role of Nanotechnologies.

31. Intracoronary bolus of glycoprotein IIb/IIIa inhibitor as bridging or adjunctive strategy to oral P2Y12 inhibitor load in the modern setting of ST-elevation myocardial infarction.

32. Great Debate: Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week.

33. Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials.

35. Antiplatelet Therapy during the First Year after Acute Coronary Syndrome in a Contemporary Italian Community of over 5 Million Subjects.

36. Bleeding Complications in Patients Undergoing Percutaneous Coronary Intervention.

37. Efficacy and safety of dual-pathway inhibition in patients with cardiovascular disease: a meta-analysis of 49 802 patients from 7 randomized trials.

39. Adherence and Persistence with Once-Daily vs Twice-Daily Direct Oral Anticoagulants Among Patients with Atrial Fibrillation: Real-World Analyses from the Netherlands, Italy and Germany.

41. Differential Proteomics of Cardiovascular Risk and Coronary Artery Disease in Humans.

42. Why Do High-Risk Patients Develop or Not Develop Coronary Artery Disease? Metabolic Insights from the CAPIRE Study.

43. Ion channel inhibition with amiodarone or verapamil in symptomatic hospitalized nonintensive-care COVID-19 patients: The ReCOVery-SIRIO randomized trial.

45. Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis.

46. Anti-inflammatory therapy in ischaemic heart disease: from canakinumab to colchicine.

Catalog

Books, media, physical & digital resources